Podcast: Navigating Challenges – The Changing Role Of Big Pharma

Podcast Interview With AstraZeneca's Stefan Woxström

Stefan Woxström, senior vice president of AstraZeneca, Europe and Canada, discusses the growing challenges in the industry and addresses the role big pharma must adopt in resolving them.

In Vivo Podcast
• Source: Shutterstock

"I have to go beyond just focusing on bringing medicine to patients but also start looking at what health care systems really need."

In this latest instalment of the In Vivo podcast, Stefan Woxström, senior VP of AstraZeneca, Europe and Canada, draws attention to the role big pharma can adopt in delivering preventative and sustainable health care. Woxström analyzes the changing role of technology in disease prevention and looks forward to the future of AstraZeneca. 

Timestamps:

Introduction - 00:00

What concerns do you hold for the future of health care? - 4:50 

How does big pharma need to act to protect innovation? – 7:20 

Role within preventative health- 11:56

Devices in medicine- 16:17

Goals for the business in the next 12-18 months- 22:04

How will work adapt to achieve these aims? - 24:00

More from Market Access

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By 

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

UK Must Put Adoption On A Par With Innovation, AZ Tells BioWales Forum

 
• By 

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.

Biotech Leaders Ponder Trump’s Tariff Ramifications

 

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

Reforming The Rx Rulers: A New Script For PBMs

 
• By 

As PBMs shift to value-based contracts, federal and state efforts seek to reduce drug costs, increase transparency and tackle anticompetitive practices.

More from In Vivo

Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Rising Leaders 2025: Christina Ziegenberg On Keeping Medtechs Competitive And MDR Compliant

 
• By 

Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.

Financing Quarterly Statistics, Q1 2025

 
• By 

During Q1, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $5bn; while in vitro diagnostic firms and research tools players raised $418m.